A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

PHASE3CompletedINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

July 31, 1997

Primary Completion Date

June 30, 1999

Study Completion Date

June 30, 1999

Conditions
Ocular HypertensionGlaucoma
Interventions
DRUG

latanoprost 0.005%

placebo in the morning and latanoprost .005% in the evening

DRUG

fixed combination latanoprost-timolol

one drop in the morning and placebo in the evening

DRUG

timolol 0.5%

one drop in the morning and evening

Trial Locations (53)

19610

Pfizer Investigational Site, Wyomissing

21117

Pfizer Investigational Site, Owings Mills

21201

Pfizer Investigational Site, Baltimore

23219

Pfizer Investigational Site, Richmond

23235

Pfizer Investigational Site, Richmond

28105

Pfizer Investigational Site, Matthews

28112

Pfizer Investigational Site, Monroe

28204

Pfizer Investigational Site, Charlotte

28210

Pfizer Investigational Site, Charlotte

28260

Pfizer Investigational Site, Charlotte

29412

Pfizer Investigational Site, Charleston

30223

Pfizer Investigational Site, East Point

Pfizer Investigational Site, Griffin

30260

Pfizer Investigational Site, Morrow

30322

Pfizer Investigational Site, Atlanta

30342

Pfizer Investigational Site, Atlanta

30349

Pfizer Investigational Site, Atlanta

33613

Pfizer Investigational Site, Tampa

34640

Pfizer Investigational Site, Largo

38119

Pfizer Investigational Site, Memphis

40207

Pfizer Investigational Site, Louisville

46515

Pfizer Investigational Site, Elkhart

46545

Pfizer Investigational Site, Mishawaka

46601

Pfizer Investigational Site, South Bend

46617

Pfizer Investigational Site, South Bend

52245

Pfizer Investigational Site, Iowa City

53705

Pfizer Investigational Site, Madison

53715

Pfizer Investigational Site, Madison

55421

Pfizer Investigational Site, Minneapolis

55422

Pfizer Investigational Site, Golden Valley

60187

Pfizer Investigational Site, Wheaton

60612

Pfizer Investigational Site, Chicago

64093

Pfizer Investigational Site, Warrensburg

64111

Pfizer Investigational Site, Kansas City

64114

Pfizer Investigational Site, Kansas City

77030

Pfizer Investigational Site, Houston

80210

Pfizer Investigational Site, Denver

92801

Pfizer Investigational Site, Anaheim

92807

Pfizer Investigational Site, Anaheim

94115

Pfizer Investigational Site, San Francisco

95819

Pfizer Investigational Site, Sacramento

95823

Pfizer Investigational Site, Sacramento

97201

Pfizer Investigational Site, Portland

97210

Pfizer Investigational Site, Portland

98431

Pfizer Investigational Site, Tacoma

80304-3573

Pfizer Investigational Site, Boulder

02111

Pfizer Investigational Site, Boston

03301

Pfizer Investigational Site, Concord

07080

Pfizer Investigational Site, South Plainfield

29464-3245

Pfizer Investigational Site, Mt. Pleasant

78731-4941

Pfizer Investigational Site, Austin

77555-1141

Pfizer Investigational Site, Galveston

Unknown

Pfizer Investigational Site, Charlottesville

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00800267 - A Study of Glaucoma or Ocular Hypertension in Patients Within the United States | Biotech Hunter | Biotech Hunter